Loading...

AVENUE THERAPEUTICS INC Management Changes 8-K Filing

VN T

AVENUE THERAPEUTICS INC

()

2024 8-K

License Agreement Signed

Annual Meeting Results

Annual Meeting Notice

Stock Purchase Agreement

Stock Delisting

Nasdaq Hearing Results

Delisting Notice

Q3 Financial Results

Equity Awards Granted

Earnings Reports

Annual Meeting Approval

Compliance with Nasdaq List...

Financial Results Announcement

Agreement for Stock Offering

Warrant Exercise Agreement

Earnings Report

Reverse Stock Split

Increase in Authorized Shares

Share Issuance and Authoriz...

Material Definitive Agreement

Earnings Report

Public Offering

Delisting Notice

License Agreement with AnnJ...

Private Placement

Earnings Report

Delisting due to Non-Compli...

Annual Meeting of Stockholders

Financial Results Announcement

FDA Meeting Minutes

Financial Results Announcement

Board Expansion and Appoint...

License Agreement with AnnJ...

Bylaws Amendment

Annual Meeting Approval

Registered Offering and Pri...

Dismissal of Independent Re...

External Links:

Avenue Therapeutics granted 170,000 restricted stock units to CEO Alexandra MacLean and 65,000 to Interim CFO David Jin, vesting in four installments from September 2024 to September 2026, contingent on continued service.

AI Assistant

AVENUE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.